{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:12Z","timestamp":1785131952935,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12185-026-04201-6","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:12:18Z","timestamp":1774923138000},"page":"228-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of clofarabine for preconditioning intervention in patients undergoing allogeneic hematopoietic stem cell transplantation for relapsed\/refractory acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"124","author":[{"given":"Akihiko","family":"Izumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-4459","authenticated-orcid":false,"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maasa","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuku","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"5","key":"4201_CR1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.bbmt.2020.01.007","volume":"26","author":"T Tachibana","year":"2020","unstructured":"Tachibana T, Kanda J, Ishizaki T, et al. Outcomes and prognostic factors for patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter analysis. Biol Blood Marrow Transplant. 2020;26(5):998\u20131004. https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.007.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"4201_CR2","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s00277-021-04607-8","volume":"100","author":"T Tachibana","year":"2021","unstructured":"Tachibana T, Kanda J, Ishizaki T, et al. Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. Ann Hematol. 2021;100(11):2763\u201371. https:\/\/doi.org\/10.1007\/s00277-021-04607-8.","journal-title":"Ann Hematol"},{"issue":"7","key":"4201_CR3","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","volume":"102","author":"H Kantarjian","year":"2003","unstructured":"Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7):2379\u201386. https:\/\/doi.org\/10.1182\/blood-2003-03-0925.","journal-title":"Blood"},{"issue":"3","key":"4201_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12185-020-03032-3","volume":"113","author":"T Saito","year":"2021","unstructured":"Saito T, Hatta Y, Hayakawa F, et al. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed\/refractory acute lymphoblastic leukemia: a phase 1\/2 dose-escalation study by the Japan Adult Leukemia Study Group. Int J Hematol. 2021;113(3):395\u2013403. https:\/\/doi.org\/10.1007\/s12185-020-03032-3.","journal-title":"Int J Hematol"},{"issue":"14","key":"4201_CR5","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1080\/10428194.2019.1639170","volume":"60","author":"R Bassan","year":"2019","unstructured":"Bassan R, Fumagalli M, Chiaretti S, et al. Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. Leuk Lymphoma. 2019;60(14):3482\u201392. https:\/\/doi.org\/10.1080\/10428194.2019.1639170.","journal-title":"Leuk Lymphoma"},{"key":"4201_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-60761-629-0_13","volume":"630","author":"H Fan","year":"2010","unstructured":"Fan H, Robetorye RS. Real-time quantitative reverse transcriptase polymerase chain reaction. Methods Mol Biol. 2010;630:199\u2013213.","journal-title":"Methods Mol Biol"},{"issue":"6","key":"4201_CR7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","volume":"17","author":"VH van der Velden","year":"2003","unstructured":"van der Velden VH, Hochhaus A, Cazzaniga G, Szczepan-ski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6):1013\u201334.","journal-title":"Leukemia"},{"issue":"1","key":"4201_CR8","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2016.008","volume":"8","author":"AA Hagag","year":"2016","unstructured":"Hagag AA, Badraia IM, Hassan SM, Abd El-Lateef AE. Prognostic impact of WT-1 gene expression in Egyptian children with acute lymphoblastic Leukemia. Mediterr J Hematol Infect Dis. 2016;8(1):e2016008. https:\/\/doi.org\/10.4084\/MJHID.2016.008.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"5","key":"4201_CR9","first-page":"540","volume":"27","author":"D Hoelzer","year":"2000","unstructured":"Hoelzer D, G\u00f6kbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol. 2000;27(5):540\u201359.","journal-title":"Semin Oncol"},{"issue":"8","key":"4201_CR10","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"issue":"6","key":"4201_CR11","first-page":"825","volume":"15","author":"D Przepiorka","year":"1994","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1994;15(6):825\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"4201_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204\u201317. https:\/\/doi.org\/10.1016\/0002-9343(80)90380-0.","journal-title":"Am J Med"},{"issue":"7","key":"4201_CR13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906\u201312. https:\/\/doi.org\/10.1038\/bmt.2016.130.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"4201_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/sj.bmt.1703142","volume":"28","author":"B Afessa","year":"2001","unstructured":"Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28(5):425\u201334. https:\/\/doi.org\/10.1038\/sj.bmt.1703142.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"4201_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.bbmt.2007.05.001","volume":"13","author":"S Yoshihara","year":"2007","unstructured":"Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(7):749\u201359. https:\/\/doi.org\/10.1016\/j.bbmt.2007.05.001.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4201_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3324\/haematol.10699","volume":"92","author":"T Ruutu","year":"2007","unstructured":"Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95\u2013100. https:\/\/doi.org\/10.3324\/haematol.10699.","journal-title":"Haematologica"},{"issue":"3","key":"4201_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"4201_CR18","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675\u201387. https:\/\/doi.org\/10.1200\/JCO.2005.07.061.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4201_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjh.14428","volume":"176","author":"O Ringd\u00e9n","year":"2017","unstructured":"Ringd\u00e9n O, Labopin M, Schmid C, et al. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2017;176(3):431\u20139. https:\/\/doi.org\/10.1111\/bjh.14428.","journal-title":"Br J Haematol"},{"issue":"9","key":"4201_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091437","volume":"8","author":"W Owattanapanich","year":"2019","unstructured":"Owattanapanich W, Ungprasert P, Wais V, Kungwankiattichai S, Bunjes D, Kuchenbauer F. FLAMSA-RIC for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis. J Clin Med. 2019;8(9):1437. https:\/\/doi.org\/10.3390\/jcm8091437.","journal-title":"J Clin Med"},{"issue":"3","key":"4201_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12185-011-0919-3","volume":"94","author":"K Arita","year":"2011","unstructured":"Arita K, Kondo T, Sugita J, et al. Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia. Int J Hematol. 2011;94(3):291\u20135. https:\/\/doi.org\/10.1007\/s12185-011-0919-3.","journal-title":"Int J Hematol"},{"issue":"3","key":"4201_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41409-019-0702-2","volume":"55","author":"AH Bazarbachi","year":"2020","unstructured":"Bazarbachi AH, Al Hamed R, Labopin M, et al. Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2020;55(3):595\u2013602. https:\/\/doi.org\/10.1038\/s41409-019-0702-2.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4201_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2360843","volume":"29","author":"T Tachibana","year":"2024","unstructured":"Tachibana T, Tanaka M, Noguchi Y, et al. Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib. Hematology. 2024;29(1):2360843. https:\/\/doi.org\/10.1080\/16078454.2024.2360843.","journal-title":"Hematology"},{"issue":"1","key":"4201_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12185-023-03688-7","volume":"119","author":"J Nukui","year":"2024","unstructured":"Nukui J, Tachibana T, Miyazaki T, et al. Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2024;119(1):62\u201370. https:\/\/doi.org\/10.1007\/s12185-023-03688-7.","journal-title":"Int J Hematol"},{"issue":"1","key":"4201_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2424053","volume":"29","author":"J Nukui","year":"2024","unstructured":"Nukui J, Tachibana T, Miyazaki T, et al. Impact of bone marrow nucleated cell subfractions on transplant outcomes in patients with acute lymphoblastic leukemia. Hematology. 2024;29(1):2424053. https:\/\/doi.org\/10.1080\/16078454.2024.2424053.","journal-title":"Hematology"},{"issue":"8","key":"4201_CR26","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/bmt.2017.58","volume":"52","author":"N Kawashima","year":"2017","unstructured":"Kawashima N, Terakura S, Nishiwaki S, et al. Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation. Bone Marrow Transplant. 2017;52(8):1164\u201370. https:\/\/doi.org\/10.1038\/bmt.2017.58.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4201_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/bmt.2013.134","volume":"49","author":"M Koyama","year":"2014","unstructured":"Koyama M, Hashimoto D, Nagafuji K, et al. Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transplant. 2014;49(1):110\u20135. https:\/\/doi.org\/10.1038\/bmt.2013.134.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"4201_CR28","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032\u201341. https:\/\/doi.org\/10.1182\/blood-2011-12-399287.","journal-title":"Blood"},{"issue":"11","key":"4201_CR29","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/cncr.30604","volume":"123","author":"J Pavl\u016f","year":"2017","unstructured":"Pavl\u016f J, Labopin M, Zoellner AK, et al. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: a report from the Acute Leukemia Working Party of the EBMT. Cancer. 2017;123(11):1965\u201370. https:\/\/doi.org\/10.1002\/cncr.30604.","journal-title":"Cancer"},{"issue":"10299","key":"4201_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8.","journal-title":"Lancet"},{"issue":"23","key":"4201_CR31","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, et al. Obecabtagene Autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391(23):2219\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2406526.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04201-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:04:42Z","timestamp":1785128682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04201-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4201"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04201-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors except the following have no conflict of interest to declare. TTachibana reports personal fees from Otsuka, personal fees from Novartis, personal fees from Pfizer, personal fees from BMS, personal fees from Daiichi Sankyo, personal fees from Astellas, outside the submitted work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of Kanagawa Cancer Center (No. 2024-eki-2) and conducted in accordance with the Helsinki declaration. The requirement for informed consent was waived by the IRB, considering that no intervention was involved due to the retrospective nature of this study.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}